Systemic Lupus Erythematosus (SLE) Treatments

Find Systemic Lupus Erythematosus (SLE) Treatments

Brand Name

Benlysta

Generic Name
Belimumab
View Brand Information
FDA approval date: March 10, 2011
Classification: B Lymphocyte Stimulator-specific Inhibitor
Form: Injection, Solution

What is Benlysta (Belimumab)?

BENLYSTA is indicated for the treatment of: patients 5 years of age and older with active systemic lupus erythematosus who are receiving standard therapy, and, patients 5 years of age and older with active lupus nephritis who are receiving standard therapy. Limitations of Use The efficacy of BENLYSTA has not been evaluated in patients with severe active central nervous system lupus. Use of BENLYSTA is not recommended in this situation. BENLYSTA is a B-lymphocyte stimulator -specific inhibitor indicated for the treatment of:, patients 5 years of age and older with active systemic lupus erythematosus who are receiving standard therapy; , patients 5 years of age and older with active lupus nephritis who are receiving standard therapy. Limitations of Use: The efficacy of BENLYSTA has not been evaluated in patients with severe active central nervous system lupus. Use of BENLYSTA is not recommended in this situation.

Approved To Treat

Top Global Experts

View All
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances

Related Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled Study of Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Study of Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Who is this study for: Patients with early diffuse cutaneous systemic sclerosis
Enrollment Status: Recruiting
Publish Date: March 27, 2026
Intervention Type: Other, Drug
Study Drugs: Belimumab, Rituximab, MMF
Study Phase: Phase 2

Summary: This is a 52 week, single center, randomized, double-blind, placebo-controlled study. After patients maintain a stable dose of Mycophenolate Mofetil (MMF) for at least 1 month, they will be randomized to treatment with either Belimumab \& Rituximab or placebo.Patients in both groups will be on background MMF for the entirety of the study. Belimumab will be administered subcutaneously and Rituximab...

The Evaluation Of Use of Belimumab in Routine Care SEttings in Lupus Nephritis (LN): the OBSErve-LN Study
The Evaluation Of Use of Belimumab in Routine Care SEttings in Lupus Nephritis (LN): the OBSErve-LN Study
Enrollment Status: Recruiting
Publish Date: March 27, 2026
Intervention Type: Other

Summary: The purpose of the OBSErve-LN study is to assess the real-world use and effectiveness of belimumab in routine practice for the treatment of adults with active LN in multiple countries of interest. This study aims to provide the first long-term (up to 5 years) assessment of renal function preservation in belimumab treated participants.

A Phase 1, First-time-in-human, Three-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK4527363 in Healthy Participants (Part A), Participants With Active Systemic Lupus Erythematosus (Part B), Healthy Participants of Chinese and Japanese Descent (Part C) and Participants With Interstitial Lung Disease Associated With Connective Tissue Disease (Part D)
A Phase 1, First-time-in-human, Three-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK4527363 in Healthy Participants (Part A), Participants With Active Systemic Lupus Erythematosus (Part B), Healthy Participants of Chinese and Japanese Descent (Part C) and Participants With Interstitial Lung Disease Associated With Connective Tissue Disease (Part D)
Enrollment Status: Recruiting
Publish Date: March 12, 2026
Intervention Type: Drug
Study Phase: Phase 1

Summary: This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of GSK4527363 in healthy participants (Part A), participants with active SLE (Part B), healthy participants of Chinese and Japanese descent (Part C), and participants with interstitial lung disease associated with connective tissue disease (Part D)

View All Clinical Trials

Related Latest Advances

Clinical outcomes of anifrolumab after belimumab failure in systemic lupus erythematosus: A single-center case series.
Clinical outcomes of anifrolumab after belimumab failure in systemic lupus erythematosus: A single-center case series.
Journal: Lupus
Published: April 13, 2026
Efficacy and safety of belimumab in IgA nephropathy: real-world evidence.
Efficacy and safety of belimumab in IgA nephropathy: real-world evidence.
Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: March 23, 2026
Aberrant bone marrow granulopoiesis generates neutrophils that promote B cell activity in neuromyelitis optica spectrum disorder.
Aberrant bone marrow granulopoiesis generates neutrophils that promote B cell activity in neuromyelitis optica spectrum disorder.
Journal: Science translational medicine
Published: March 11, 2026
View All Latest Advances